Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons
I give below details of changes in the Directors' interests in the Ordinary Shares and American Depositary Shares (ADSs) of GlaxoSmithKline plc.
On 31 March 2014, the Company's Non-Executive Directors were allocated notional Ordinary Shares at a price of £16.08 per Ordinary Share, and notional ADSs at a price of $53.75 per ADS under the share allocation arrangements for Non-Executive Directors for the period of service from 1 January 2014 to 31 March 2014:
Non Executive Director |
Ordinary Shares |
American Depositary Shares (ADSs) |
|
|
|
Sir Christopher Gent |
3,886.816 |
|
|
|
|
Professor Sir Roy Anderson |
563.588 |
|
|
|
|
Dr Stephanie Burns |
|
433.042 |
|
|
|
Stacey Cartwright |
446.984 |
|
|
|
|
Lynn Elsenhans |
|
779.475 |
|
|
|
Judy Lewent |
|
367.144 |
|
|
|
Sir Deryck Maughan |
|
1,092.019 |
|
|
|
Dr Daniel Podolsky |
|
819.014 |
|
|
|
Tom de Swaan |
408.116 |
|
|
|
|
Jing Ulrich |
|
216.521 |
|
|
|
Hans Wijers |
446.984 |
|
|
|
|
Sir Robert Wilson |
446.984 |
|
|
|
|
The Company and the Non-Executive Directors were informed of these allocations on 1 April 2014.
This notification relates to transactions notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
V A Whyte
Company Secretary
2 April 2014